Literature DB >> 22365779

Generation of hairpin-based RNAi vectors for biological and therapeutic application.

Ryan L Boudreau1, Beverly L Davidson.   

Abstract

RNA interference (RNAi) is a natural process of gene silencing mediated by small RNAs. Shortly after the discovery of the RNAi mechanism, scientists devised various methods of delivering small interfering RNAs (siRNAs) capable of co-opting the endogenous RNAi machinery and suppressing target gene expression based on sequence complementarity. RNAi has since become a powerful tool to study gene function and is being investigated as a potential therapeutic approach to treat a vast array of human diseases (e.g., cancer, viral infections, and dominant genetic disorders). Among the available RNAi vectors are hairpin-based expression platforms (short-hairpin RNAs and artificial microRNAs) designed to mimic endogenously expressed inhibitory RNAs. These RNAi vectors are capable of achieving long-term potent gene silencing in vitro and in vivo. Here, we describe methods to design and generate these hairpin-based vectors and briefly review considerations for downstream applications. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365779     DOI: 10.1016/B978-0-12-386509-0.00014-4

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  17 in total

Review 1.  Recent advances in RNA interference therapeutics for CNS diseases.

Authors:  Pavitra S Ramachandran; Megan S Keiser; Beverly L Davidson
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 2.  Recombinant AAV as a platform for translating the therapeutic potential of RNA interference.

Authors:  Florie Borel; Mark A Kay; Christian Mueller
Journal:  Mol Ther       Date:  2013-12-19       Impact factor: 11.454

Review 3.  Oligonucleotide therapeutics in neurodegenerative diseases.

Authors:  Daniel R Scoles; Stefan M Pulst
Journal:  RNA Biol       Date:  2018-06-01       Impact factor: 4.652

4.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

5.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.

Authors:  Pavitra S Ramachandran; Ryan L Boudreau; Kellie A Schaefer; Albert R La Spada; Beverly L Davidson
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

6.  Regulation of (pro)renin receptor expression in mIMCD via the GSK-3β-NFAT5-SIRT-1 signaling pathway.

Authors:  Syed Quadri; Helmy M Siragy
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-02

7.  A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications.

Authors:  Qiu-Xia Chen; Wei-Peng Wang; Su Zeng; Shiro Urayama; Ai-Ming Yu
Journal:  Nucleic Acids Res       Date:  2015-03-23       Impact factor: 16.971

8.  RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.

Authors:  Pavitra S Ramachandran; Sajag Bhattarai; Pratibha Singh; Ryan L Boudreau; Stewart Thompson; Albert R Laspada; Arlene V Drack; Beverly L Davidson
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

9.  Sonic Hedgehog Controls the Phenotypic Fate and Therapeutic Efficacy of Grafted Neural Precursor Cells in a Model of Nigrostriatal Neurodegeneration.

Authors:  Lalitha Madhavan; Brian F Daley; Beverly L Davidson; Ryan L Boudreau; Jack W Lipton; Allyson Cole-Strauss; Kathy Steece-Collier; Timothy J Collier
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

10.  Effective Targeted Gene Knockdown in Mammalian Cells Using the piggyBac Transposase-based Delivery System.

Authors:  Jesse B Owens; Juanita Mathews; Philip Davy; Ilko Stoytchev; Stefan Moisyadi; Rich Allsopp
Journal:  Mol Ther Nucleic Acids       Date:  2013-12-10       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.